Immunovant Provides Corporate Updates and Reports Financial

29.05.2024 - Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ...

Related Keywords

Chau Cheng , Exchange Commission , Neurology Clinical Development Updates , Due To Roivant Sciences Ltd , General Clinical Development Updates , Endocrinology Clinical Development Updates , Immunovant Inc , Clinical Development Updates , Thyroid Eye Disease , Insulin Growth Factor , Fiscal Fourth Quarter Ended March , Fiscal Year Ended March , Private Securities Litigation Reform Act , Annual Report , Roivant Sciences ,